NSABP B-31 trial
A US, Phase III, randomised, multicentre, open-label trial in the adjuvant setting comparing doxorubicin and cyclophosphamide followed by paclitaxel, with the same regimen plus 1 year of Herceptin in HER2-positive EBC.
- Disclaimer: Herceptin.net is a comprehensive resource for healthcare professionals outside the US. If you are a US resident please visit www.herceptin.com. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
- © 2010 F. Hoffmann-La Roche Ltd.